Tysabri, J&J deal and lower spending boost Elan but tax charge hits bottom line
This article was originally published in Scrip
Executive Summary
Higher sales of its top-selling multiple sclerosis drug Tysabri (natalizumab), the benefits of its deal with Johnson & Johnson and reduced R&D and SG&A spending all helped improve Elan's financial results in 2009. Revenues were up by 11% to $1.1 billion and net loss before tax significantly was reduced from $297 million to $130 million.